THIS PAGE IS UNDER CONSTRUCTION
Related Pages
Dopamine D2 receptor polymorphisms and response to antipsychotic medications
Pharmacogenomics and psychotropic medications
References
Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D, Malhotra AK. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics. 2010 Sep;20(9):569-72. doi: 10.1097/FPC.0b013e32833ca24b. PubMed PMID: 20664489; PubMed Central PMCID: PMC2920359
Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Ishida M, Furukori H, Kaneko S, Inoue Y, Otani K. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics. 2001 Aug;11(6):545-50. PubMed PMID: 11505224.
Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. PubMed PMID: 15694263.
Xing Q, Qian X, Li H, Wong S, Wu S, Feng G, Duan S, Xu M, Gao R, Qin W, Gao J, Meng J, He L. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol. 2007 Oct;10(5):631-7. PubMed PMID: 17105675.
Copyright © 2017, Simple and Practical Mental Health. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.